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The PPAR family of nuclear receptor transcription factors
are important regulators of cardiovascular function and
metabolism. Because of this, PPARs are potentially interest-
ing pharmacologic targets for treating cardiometabolic dis-
ease. The reviews in this series discuss the regulatory func-
tions of PPARs in maintaining metabolic and physiologic
homeostasis in a variety of cells and tissues. Additionally, the
therapeutic potential and mechanisms of action of ligands of
the diﬀerent PPAR isotypes are discussed.
The review series is started by an examination of the ef-
fects of PPARs on lipoprotein metabolism. This is one of
the ﬁrst identiﬁed functions of PPARs. Indeed, ligands for
PPARα were in clinical use as lipid-lowering agents even be-
fore their pharmacological target, PPARα, were known. The
secondreviewevaluatestheimportantanti-inﬂammatoryef-
fects of PPARs in platelets, which is emerging as an impor-
tant mechanism of their beneﬁcial eﬀects. Next, the critical
role that PPARα and its transcriptional coactivator protein
PGC-1α play in regulating energy metabolism and function
of the myocardium is discussed. Then, a series of reviews fo-
cuses on the potentially beneﬁcial eﬀects of PPARγ agonists
on the cardiovascular system. Several aspects are presented.
The eﬀects of PPAR activation on the cardiovascular system
as a whole, on the vascular smooth muscle cell, and in the
context of diabetic cardiovascular disease are each discussed
at length. A review by Demers et al. also discusses the po-
tential input of the hexarelin signaling pathway in regulating
PPARγ activity and its potential impact on cardiometabolic
disease. The genes encoding the PPARs are rich with genetic
variation and the impact of these polymorphisms and hap-
lotypes on the response to PPAR activators is only beginning
to be understood. Thus, the “pharmacogenomics” of PPARs
are discussed in a review by Dr. Sharon Cresci. Finally, the
potential toxicity and adverse outcomes of PPAR agonism
are summarized in detail by Jennifer Robinson. The timeli-
ness of this discussion is outstanding given the recent reports
of increased cardiovascular morbidity associated with use of
rosiglitazone and the failure of PPAR dual agonists at diﬀer-
entstagesofdevelopment.Severaloftheotherreviewsinthis
series also touch this controversial issue at least brieﬂy.
We are also pleased to present two original research re-
ports. The ﬁrst report found associations between PPARγ
gene polymorphisms and several cardiometabolic indices,
butfoundnolinkwithcardiovascularmorbidityandmortal-
ity. Second, Buroker et al. report an important role for PGC-
1α in postnatal metabolic maturation. This preprogrammed
burst in cardiac oxidative metabolism is an important de-
velopmental response that also has implications for other
physiologic states wherein the demand for ATP production
is rapidly induced.
We hope that you will ﬁnd this issue enjoyable and infor-
mative.
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